Pramipexole in the Management of Parkinson’s Disease
- 2 June 2008
- journal article
- Published by Taylor & Francis in Aging Health
- Vol. 4 (3) , 225-235
Abstract
Parkinson’s disease (PD) is a complex neurodegenerative disease with both motor and nonmotor symptoms. The major clinical symptoms of PD are due to dopamine deficiency caused by the degeneration of nigrostriatal dopaminergic neurons. As a consequence, current treatments remain focused on the dopamine system. Dopamine-replacement therapy with levodopa has been the mainstay of symptomatic treatment of PD for nearly 40 years. However, levodopa-induced motor complications have led many physicians to advocate alternative options for treatment initiation in suitable patients or as an adjunctive therapy in more advanced cases.Keywords
Funding Information
- GSK, Pfizer, Eli Lilly, Novartis, TEVA, Lundbeck, Bayer Health Care, Solvay, Desitin, Cephalon
This publication has 77 references indexed in Scilit:
- Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's diseaseThe Lancet Neurology, 2007
- Why hasn't neuroprotection worked in Parkinson's disease?Nature Clinical Practice Neurology, 2007
- Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader‐blinded monocenter echocardiography studyMovement Disorders, 2006
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- L-DOPA: From a biologically inactive amino acid to a successful therapeutic agentAmino Acids, 2002
- Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patientsJournal of Neural Transmission, 2002
- Olfactory dysfunction in parkinsonismNeurology, 1988
- Bromocriptine in ParkinsonismBMJ, 1974
- Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agentJournal of Pharmacy and Pharmacology, 1973
- Similarities between Neurologic Effects of L-Dopa and of ApomorphineNew England Journal of Medicine, 1970